Insider Transactions in Q1 2021 at Adaptive Biotechnologies Corp (ADPT)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 31
2021
|
Stacy L Taylor SVP and General Counsel |
SELL
Open market or private sale
|
Direct |
4,167
-21.7%
|
$166,680
$40.0 P/Share
|
|
Mar 31
2021
|
Stacy L Taylor SVP and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
4,167
+7.23%
|
$62,505
$15.35 P/Share
|
|
Mar 25
2021
|
Harlan S Robins Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
5,290
-3.6%
|
$201,020
$38.43 P/Share
|
|
Mar 25
2021
|
Harlan S Robins Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,290
+6.62%
|
$31,740
$6.32 P/Share
|
|
Mar 24
2021
|
Harlan S Robins Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
6,395
-2.87%
|
$255,800
$40.51 P/Share
|
|
Mar 24
2021
|
Harlan S Robins Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,395
+7.78%
|
$38,370
$6.32 P/Share
|
|
Mar 23
2021
|
Harlan S Robins Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
7,790
-10.1%
|
$319,390
$41.93 P/Share
|
|
Mar 23
2021
|
Harlan S Robins Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,790
+9.17%
|
$46,740
$6.32 P/Share
|
|
Mar 19
2021
|
Chad M Robins CEO and Chairman |
SELL
Open market or private sale
|
Direct |
5,000
-0.14%
|
$210,000
$42.22 P/Share
|
|
Mar 18
2021
|
Jyoti Palaniappan SVP, Diagnostics, T-Detect |
SELL
Open market or private sale
|
Direct |
16,052
-28.15%
|
$706,288
$44.06 P/Share
|
|
Mar 18
2021
|
Jyoti Palaniappan SVP, Diagnostics, T-Detect |
BUY
Exercise of conversion of derivative security
|
Direct |
16,052
+38.9%
|
$353,144
$22.55 P/Share
|
|
Mar 18
2021
|
Chad M Robins CEO and Chairman |
SELL
Open market or private sale
|
Direct |
5,000
-0.09%
|
$210,000
$42.83 P/Share
|
|
Mar 17
2021
|
Katey Einterz Owen Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,443
+50.0%
|
-
|
|
Mar 17
2021
|
Leslie Trigg Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,443
+50.0%
|
-
|
|
Mar 17
2021
|
Chad M Robins CEO and Chairman |
SELL
Open market or private sale
|
Direct |
5,000
-0.09%
|
$220,000
$44.17 P/Share
|
|
Mar 16
2021
|
Michelle Renee Griffin Director |
SELL
Open market or private sale
|
Direct |
1,500
-49.93%
|
$70,500
$47.0 P/Share
|
|
Mar 16
2021
|
Michelle Renee Griffin Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+33.3%
|
$10,500
$7.8 P/Share
|
|
Mar 15
2021
|
Francis Lo Chief People Officer |
SELL
Open market or private sale
|
Direct |
2,000
-4.52%
|
$82,000
$41.8 P/Share
|
|
Mar 15
2021
|
Francis Lo Chief People Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+8.13%
|
$14,000
$7.8 P/Share
|
|
Mar 15
2021
|
Sharon Benzeno Chief Commercial Ofc Imm Med |
SELL
Open market or private sale
|
Direct |
1,354
-2.82%
|
$55,514
$41.54 P/Share
|
|
Mar 15
2021
|
Sharon Benzeno Chief Commercial Ofc Imm Med |
BUY
Exercise of conversion of derivative security
|
Direct |
1,354
+5.29%
|
$41,974
$31.71 P/Share
|
|
Mar 15
2021
|
Michelle Renee Griffin Director |
SELL
Open market or private sale
|
Direct |
4,500
-42.71%
|
$184,500
$41.53 P/Share
|
|
Mar 15
2021
|
Michelle Renee Griffin Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,500
+42.84%
|
$31,500
$7.8 P/Share
|
|
Mar 10
2021
|
Chad M Cohen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
10,000
-31.64%
|
$420,000
$42.54 P/Share
|
|
Mar 10
2021
|
Chad M Cohen Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+24.04%
|
$60,000
$6.32 P/Share
|
|
Mar 10
2021
|
David E. Goel Director |
SELL
Open market or private sale
|
Indirect |
56,000
-0.23%
|
$2,296,000
$41.93 P/Share
|
|
Mar 09
2021
|
Chad M Cohen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
10,000
-17.48%
|
$400,000
$40.41 P/Share
|
|
Mar 09
2021
|
Chad M Cohen Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+24.35%
|
$60,000
$6.32 P/Share
|
|
Mar 09
2021
|
David E. Goel Director |
SELL
Open market or private sale
|
Indirect |
250,000
-0.99%
|
$10,000,000
$40.79 P/Share
|
|
Mar 08
2021
|
Robert Hershberg Director |
SELL
Open market or private sale
|
Direct |
4,000
-78.54%
|
$176,000
$44.56 P/Share
|
|
Mar 08
2021
|
Robert Hershberg Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+43.17%
|
$0
$0.45 P/Share
|
|
Mar 08
2021
|
David E. Goel Director |
SELL
Open market or private sale
|
Indirect |
500,000
-0.77%
|
$20,000,000
$40.05 P/Share
|
|
Mar 04
2021
|
Susan Bobulsky Chief Commercial Officer, MRD |
BUY
Grant, award, or other acquisition
|
Direct |
9,158
+50.0%
|
-
|
|
Mar 04
2021
|
Chad M Cohen Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,604
+48.82%
|
-
|
|
Mar 04
2021
|
Chad M Robins CEO and Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
68,681
+3.72%
|
-
|
|
Mar 04
2021
|
Francis Lo Chief People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,604
+50.0%
|
-
|
|
Mar 04
2021
|
Sharon Benzeno Chief Commercial Ofc Imm Med |
BUY
Grant, award, or other acquisition
|
Direct |
22,894
+50.0%
|
-
|
|
Mar 04
2021
|
R Mark Adams Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,604
+22.59%
|
-
|
|
Mar 04
2021
|
Jyoti Palaniappan SVP, Diagnostics, T-Detect |
BUY
Grant, award, or other acquisition
|
Direct |
9,158
+50.0%
|
-
|
|
Mar 04
2021
|
Stacy L Taylor SVP and General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
13,736
+47.74%
|
-
|
|
Mar 04
2021
|
Harlan S Robins Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
68,681
+49.75%
|
-
|
|
Mar 04
2021
|
Julie Rubinstein President |
BUY
Grant, award, or other acquisition
|
Direct |
45,788
+50.0%
|
-
|
|
Mar 04
2021
|
Lance Baldo Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
22,894
+50.0%
|
-
|
|
Mar 01
2021
|
Sharon Benzeno Chief Commercial Ofc Imm Med |
SELL
Open market or private sale
|
Direct |
6,771
-95.86%
|
$385,947
$57.87 P/Share
|
|
Mar 01
2021
|
Sharon Benzeno Chief Commercial Ofc Imm Med |
BUY
Exercise of conversion of derivative security
|
Direct |
6,771
+34.03%
|
$40,626
$6.79 P/Share
|
|
Mar 01
2021
|
Michael J Pellini Director |
SELL
Open market or private sale
|
Direct |
20,000
-100.0%
|
$1,140,000
$57.8 P/Share
|
|
Mar 01
2021
|
Michael J Pellini Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+50.0%
|
$120,000
$6.55 P/Share
|
|
Mar 01
2021
|
Julie Rubinstein President |
SELL
Open market or private sale
|
Direct |
15,000
-74.35%
|
$870,000
$58.39 P/Share
|
|
Mar 01
2021
|
Julie Rubinstein President |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
$90,000
$6.55 P/Share
|
|
Feb 26
2021
|
Stacy L Taylor SVP and General Counsel |
SELL
Open market or private sale
|
Direct |
2,812
-30.02%
|
$154,660
$55.44 P/Share
|